Alexander Chehrazi-Raffle

Journal of Immunotherapy for Cancer · 2018

A researcher in the Science corpus: 1 paper; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Papers from Alexander Chehrazi-Raffle's perspective

Ordered by how strongly the researchers Alexander Chehrazi-Raffle trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single arm, phase 2 trial (The Lancet)
  2. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. (The Lancet)
  3. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma (New England Journal of Medicine)
  4. Pembrolizumab for the treatment of non-small-cell lung cancer. (New England Journal of Medicine)
  5. Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma (New England Journal of Medicine)
  6. Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma (New England Journal of Medicine)
  7. Nivolumab versus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer (New England Journal of Medicine)
  8. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma (New England Journal of Medicine)
  9. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. (The Lancet Oncology)
  10. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (New England Journal of Medicine)

Their papers